$BNR

Burning Rock Biotech (BNR) recently reported its Q3 2025 results, showing a reduction in net losses but persistent unprofitability. Despite steady revenue around C¥130 million quarterly and C¥539.3 million trailing 12-month revenue, the company posted a C¥16.8 million loss in Q3 2025, challenging bullish arguments without clearer margin progress. The stock trades at a lower price-to-sales ratio (3.1x) compared to peers, coupled with high share price volatility, highlighting investor concerns about sustained losses.